Lercaton (Lercanidipine Hydrochloride)

Lercanidipine blocks L‑type calcium channels in the smooth muscle of arterial walls. This inhibition prevents calcium‑driven contraction, causing the vessels to relax and widen (vasodilation), which lowers peripheral resistance and consequently reduces blood pressure.

The appropriate dose of Lercaton is determined by a qualified prescriber based on the individual’s clinical condition, response to therapy, and any co‑existing medical issues. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the dose on their own.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their physician.

To place an order, submit an enquiry on the Lercaton product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lercaton belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with beta‑blockers, it has less effect on heart rate, and unlike ACE inhibitors, it does not interfere with the renin‑angiotensin system. Its once‑daily dosing and favorable tolerability profile make it a convenient option for many patients.

Lercaton tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Lercaton is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, and angioedema that can compromise the airway. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, chest pain, or swelling of the face, lips, tongue, or throat.

Lercaton is contraindicated in individuals with known hypersensitivity to lercanidipine or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, unstable angina, or those taking strong CYP3A4 inhibitors, as these conditions may increase the risk of adverse effects.